Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Targeting HER2 in Gastroesophageal Cancer: A New Approach to an Ongoing Challenge

    The incidence of gastroesophageal cancers is on the rise, driven by factors such as obesity and gastroesophageal reflux. Despite increased awareness and screening efforts, many cases are diagnosed at an advanced, unresectable stage, making effective systemic treatments critical for improving survival and quality of life.

    2025.02.05
  • Comparing Entecavir and Tenofovir Alafenamide in Chronic Hepatitis B: A Long-Term Observational Study

    In January 2025, Scientific Reports published an observational pilot study evaluating the long-term efficacy and safety of entecavir (ETV) versus tenofovir alafenamide (TAF) in patients with chronic hepatitis B.Key Findings:After…

    2025.02.05
  • Consensus on Clinical Trial Design for Acute Severe Ulcerative Colitis (ASUC)

    A new international Delphi consensus led by valuable researchers provides crucial guidance on the design and endpoints of clinical trials for Acute Severe Ulcerative Colitis (ASUC). This comprehensive consensus, developed with input from global experts, establishes 30 key statements that define essential aspects of ASUC trial design.

    2025.02.05
  • Spotlight on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis

    A recent publication in Gastroenterology provides an in-depth overview of the latest guidelines for the pharmacological management of moderate-to-severe ulcerative colitis (UC). The evolving landscape of UC treatment highlights the importance of personalized approaches, balancing efficacy, safety, and patient preferences.

    2025.02.05
  • Preventing MASLD-Related Hepatocellular Carcinoma: Insights from Clinical Gastroenterology and Hepatology

    In January 2025, Clinical Gastroenterology and Hepatology published a narrative review titled “Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma.”With MASLD (Metabolic Dysfunction-associated Steatotic…

    2025.02.05
  • Unveiling a New Perspective on Colorectal Cancer: The Role of Unresolved Inflammation

    A recent study published in Gut offers groundbreaking insights into colorectal cancer (CRC), revealing that the disease may persist in a state of chronic, unresolved inflammation, akin to a poorly healing wound. Researchers utilized advanced techniques, including lipidomics, single-cell, and spatial transcriptomics, to identify a critical imbalance within the tumor microenvironment.

    2025.02.05
  • INTEGRATE IIa Phase III Study: Regorafenib Shows Survival Benefits in Refractory Advanced Gastric Cancer

    Valuable researchers have delivered promising results from the INTEGRATE IIa Phase III trial, evaluating regorafenib, an oral multikinase inhibitor, in patients with refractory advanced gastric and esophagogastric junction cancer (AGOC).

    2025.02.05
  • Exploring Porto-Sinusoidal Vascular Disorder (PSVD) Beyond Portal Hypertension: Insights from the Journal of Hepatology

    In January 2025, the Journal of Hepatology published a thought-provoking letter titled “Beyond Portal Hypertension: Characterizing Porto-Sinusoidal Vascular Disorder in Patients without Signs of PH.” This study sheds new light…

    2025.02.05
«previous next»
Recent Posts
  • How to Develop Personalized Bladder-Preserving Strategies for MIBC? Professor Yijun Shen Shares MDT Experience and Clinical Decision Pathways
  • Professor Lei Fan: The Evolving Landscape and Future Directions of First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) | 2026 CSCO Hematologic Oncology Conference
  • Professor Erlie Jiang: Platform Synergy, Evidence Empowerment, and Grassroots Equity — Outcomes of the 2025 CSCO Leukemia Guideline Roadshow and the 2026 Strategic Blueprint
  • Professor Lugui Qiu: Upholding Integrity, Driving Innovation—CSCO Myeloma Expert Committee 2025 Work Summary and 2026 Strategic Plan
  • Annual Review | Professor Xiuli Ju: Advances in the Diagnosis and Treatment of Pediatric Mature B-Cell Lymphoma
Recent Comments
    Archives
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top